![Nektar Therapeutics logo](/logos/NKTR.webp)
Nektar Therapeutics
NASDAQ:NKTR
Overview | Financials
Company Name | Nektar Therapeutics |
Symbol | NKTR |
Currency | USD |
Price | 1.12 |
Market Cap | 206,168,480 |
Dividend Yield | 0% |
52-week-range | 0.41 - 1.93 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Howard W. Robin |
Website | https://www.nektar.com |
An error occurred while fetching data.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD